Could the solution to increasing suicide and
depression rates among members of the U.S. military lie in a nasal
spray? The Army hopes so.
In the midst of a crisis that saw its highest rate of suicide in
July, the Army has greenlighted a grant for Dr. Michael Kubek, an
Indiana University of Medicine professor, to dig deeper into whether a
nasal spray could be a safe and effective way to administer a specific
antidepressive neurochemical to the brain and help calm suicidal
thoughts.
Kubek helped discover thyrotropin-releasing hormone, or TRH, which is
known to have antisuicidal and antidepression effects. The problem is
that the naturally occurring chemical cannot easily cross the
“blood-brain barrier.” The barrier is meant to protect the nervous
system by keeping out any substances in the blood that could injure the
brain, including hormones and neurotransmitters. But it also makes it
extremely difficult to get TRH to the brain, rendering normal methods of
delivering the chemical, through pills or injection, largely unhelpful.
The military is hoping Kubek, an associate professor of anatomy and
cell biology and of neurobiology, can use a three-year grant to work
with other researchers to use a nasal spray to get TRH safely into the
brain and calm soldiers' thoughts.
Kubek's research was spotted by Navy physician Capt. Neal Naito
several years ago, according to a news release from Indiana University.
Naito, who had been the director of public health for the Navy but is
now retired, reached out to Kubek to see whether his research might be
applied to active military members and veterans.
The
Army reported 242 suicides in 2009, 305 in 2010 and 283 in 2011.
“These deaths are troubling and tragic,” Kubek said in a statement.
“Today’s commonly used anti-depressants can take weeks to have an effect
and carry a black box warning label for suicidal ideation in young
adults. That is why we hope to develop a quick-acting, easy-to-use,
non-invasive system that delivers a compound that’s been shown to reduce
suicidal thoughts.”
Secretary of Defense Leon Panetta told a congressional committee last
month that the U.S. military was facing an "epidemic" of suicides and
was in need of improvements in mental health services for active-duty
and returning troops.
The military spends about $2 billion a year on mental health for its
members. But many who study and report on military suicides say the
stigma attached to depression as well as the red tape involved in
implementing a program make it difficult to attack the problem in the
aggressive way that is needed.
Time magazine Deputy Washington Bureau Chief Mark Thompson says a
former high-ranking Army officer told him, “there are promising
techniques that the military could deploy against suicide, but they
involve an initial two-hour screening, a sit-down, a one-on-one with a
psychiatrist that this nation is just not willing to pay for.”
Kubek's techniques could be promising. It will take a few years to know, but it's research the Army knows is important.
"Suicide is the toughest enemy I have faced in my 37 years in the
Army. And it's an enemy that's killing not just Soldiers, but tens of
thousands of Americans every year," Gen. Lloyd J. Austin III, vice chief
of staff of the Army, said in a written statement after the July
release of suicide statistics.
"That said, I do believe suicide is
preventable. To combat it effectively will require sophisticated
solutions aimed at helping individuals to build resiliency and
strengthen their life coping skills."
Kubek will work with pharmacology professor Abraham Domb from Hebrew
University in Jerusalem to figure out how to deliver the drug
effectively. That process, according to Indiana University’s School of
Medicine, should take about a year. Kubek would then work with
researchers at Purdue University on clinical trials in the second and
third years of the grant.